Ibrance

Active Ingredient(s): Palbociclib
FDA Approved: * February 3, 2015
Pharm Company: * PFIZER INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Ibrance Overview

Palbociclib (codenamed PD-0332991, trade name Ibrance) is a drug for the treatment of ER-positive and HER2-negative breast cancer developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.[1][2] Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy by any organization, and as of December 2017 has been prescribed more than 90,000 times.[3] Contents 1 Mechanism of action 2 Administra...

Read more Ibrance Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Palbociclib

Recent Ibrance Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Palbociclib
  • Capsule: 100mg, 125mg, 75mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Ibrance: (6 results)

Sorted by National Drug Code
  • 0069-0187 Ibrance 75 mg Oral Capsule by Pfizer Laboratories Div Pfizer Inc
  • 0069-0188 Ibrance 100 mg Oral Capsule by Pfizer Laboratories Div Pfizer Inc
  • 0069-0189 Ibrance 125 mg Oral Capsule by Pfizer Laboratories Div Pfizer Inc
  • 63539-187 Ibrance 75 mg Oral Capsule by U.S. Pharmaceuticals
  • 63539-188 Ibrance 100 mg Oral Capsule by U.S. Pharmaceuticals
  • 63539-189 Ibrance 125 mg Oral Capsule by U.S. Pharmaceuticals

Other drugs which contain Palbociclib or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 20 April 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA